Related Experiment Videos
Malignant bone tumors in children: Ewing's sarcoma.
1Department of Pediatrics, Cornell University Medical College, New York, New York.
Hematology/Oncology Clinics of North America
|December 1, 1987
Summary
Ewing's sarcoma, a rare bone cancer, requires multiagent chemotherapy for survival. Combining chemotherapy with radiation or surgery improves local control, while bone marrow transplants may benefit high-risk patients.
Area of Science:
- Oncology
- Orthopedic Oncology
- Pediatric Oncology
Background:
- Ewing's sarcoma is a rare, malignant small round-cell tumor primarily affecting long bones.
- It can occur in any bone, presenting unique diagnostic and treatment challenges.
- Effective chemotherapy is crucial for patient survival and disease management.
Purpose of the Study:
- To summarize the current understanding and management of Ewing's sarcoma.
- To highlight the importance of multiagent chemotherapy protocols.
- To discuss the role of local treatment modalities and advanced therapies.
Main Methods:
- Review of existing literature on Ewing's sarcoma treatment.
- Analysis of treatment outcomes based on disease stage and location.
- Evaluation of the efficacy of chemotherapy, radiation, surgery, and bone marrow transplantation.
Main Results:
- Multiagent chemotherapy protocols demonstrate superior efficacy compared to single-agent therapies.
- Combined modality treatment (chemotherapy with radiation or surgery) significantly improves local tumor control.
- Metastatic disease and pelvic primary tumors are associated with a poorer prognosis.
Conclusions:
- Chemotherapy is fundamental for achieving long-term survival in Ewing's sarcoma.
- Integrated treatment approaches combining systemic and local therapies are essential.
- Autologous bone marrow transplantation offers potential for improved outcomes in select high-risk patient groups.